Home Bratislava Medical Journal 2020 Bratislava Medical Journal Vol.121, No.4, p.263–270,2020

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.121, No.4, p.263–270,2020

Title: Mesenchymal stem cell condition medium enhanced cell viability in morphine-treated cells
Author: H. Zhaleh, A. Bidmeshki Pour, M. Azadbakht

Abstract: Bone marrow mesenchymal stem cells (BM-MSC) have recently been predicted to have a major therapeutic potential due to secretion of soluble factors and the release of cytokines and growth factors, which could mediate the cellular communication to induce cell differentiation/maturity.
The aim of the present study was to determine the effect of mBM condition medium on morphine-induced cell death in PC12, U87, AGS and MCF-7 cell lines. The condition media were harvested as mBM soup (mBM soup 24 and mBM soup 48h, respectively). To investigate the effect of mBM soup on cell lines, morphological changes were studied with an inverted microscope, the viability of cells was determined with trypan blue staining and MTT assay, the type of cell death was determined using Hoescht / PI staining, and NO secretion analysis.
Viability assay showed that mBM soup (24 and 48 h) in time-dependent manner increased cell viability (pndings suggest that mBM soup can enhance the proliferation and growth of cell lines and can suppress cell death induced by morphine (Fig. 8, Ref. 59). Text in PDF www.elis.sk.

Keywords: morphine, BM-MSC soup, cell viability, cell death, NO.
Published online: 03-Apr-2020
Year: 2020, Volume: 121, Issue: 4 Page From: 263, Page To: 270

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.